Tranexamic acid is used both pre-hospital and in-hospital as an antifibrinolytic drug to treat or prevent hyperfibrinolysis in trauma patients; dosing, however, remains empirical. We aimed to measure plasma levels of tranexamic acid in patients receiving pre-hospital anti-hyperfibrinolytic therapy and to build a population pharmacokinetic model to propose an optimised dosing regimen. Seventy-three trauma patients were enrolled and each received tranexamic acid 1 g intravenously pre-hospital. A blood sample was drawn after arrival in the emergency department, and we measured the plasma tranexamic acid concentration using liquid chromatography-mass spectrometry, and modelled the data using non-linear mixed effect modelling. Tranexamic acid was administered at a median (IQR [range]) time of 43 (30-55 [5-135]) min after trauma. Plasma tranexamic acid levels were determined on arrival at hospital, 57 (43-70 [20-148]) min after pre-hospital administration of the drug. The measured concentration was 28.7 (21.5-38.5 [8.7-89.0]) lg.ml À1 . Our subjects had sustained severe trauma; injury severity score 20 (16-29 [5-75]), including penetrating injury in 2.8% and isolated traumatic brain injury in 19.7%. The pharmacokinetics were ascribed a two-compartment open model with body-weight as the main covariate. As tranexamic acid concentrations may fall below therapeutic levels during initial hospital treatment, we propose additional dosing schemes to maintain a specific target blood concentration for as long as required. This is the first study to investigate plasma level and pharmacokinetics of tranexamic acid after pre-hospital administration in trauma patients. Our proposed dosing regimen could be used in subsequent clinical trials to better study efficacy and tolerance profiles with controlled blood concentrations.
Summary
Tranexamic acid is used both pre-hospital and in-hospital as an antifibrinolytic drug to treat or prevent hyperfibrinolysis in trauma patients; dosing, however, remains empirical. We aimed to measure plasma levels of tranexamic acid in patients receiving pre-hospital anti-hyperfibrinolytic therapy and to build a population pharmacokinetic model to propose an optimised dosing regimen. Seventy-three trauma patients were enrolled and each received tranexamic acid 1 g intravenously pre-hospital. A blood sample was drawn after arrival in the emergency department, and we measured the plasma tranexamic acid concentration using liquid chromatography-mass spectrometry, and modelled the data using non-linear mixed effect modelling. Tranexamic acid was administered at a median (IQR [range]) time of 43 (30-55 [5-135] ) min after trauma. Plasma tranexamic acid levels were determined on arrival at hospital, 57 (43-70 [20-148] ) min after pre-hospital administration of the drug. The measured concentration was 28.7 (21.5-38.5 [8.7-89 .0]) lg.ml
À1
. Our subjects had sustained severe trauma; injury severity score 20 (16-29 [5-75] ), including penetrating injury in 2.8% and isolated traumatic brain injury in 19.7%. The pharmacokinetics were ascribed a two-compartment open model with body-weight as the main covariate. As tranexamic acid concentrations may fall below therapeutic levels during initial hospital treatment, we propose additional dosing schemes to maintain a specific target blood concentration for as long as required. This is the first study to investigate plasma level and pharmacokinetics of tranexamic acid after pre-hospital administration in trauma patients. Our proposed dosing regimen could be used in subsequent clinical trials to better study efficacy and tolerance profiles with controlled blood concentrations. 
Introduction
Trauma is the leading cause of death in people aged 5-45 years [1] . About 25% of severely traumatised patients develop acute trauma-induced coagulopathy, which is associated with increased risk of multi-organ failure and death [2] [3] [4] . Approximately one-third of patients die from resulting haemorrhage [5] . Haemorrhagic shock leads to a massive release of tissue plasminogen activator (tPA), and data from animal models of traumatic injuries also suggest a delayed release of urokinase plasminogen activator (uPA) [6] . Physiologically, both factors catalyse the conversion of plasminogen to active plasmin, which induces controlled anticoagulation and clot breakdown. The increased release during trauma has been shown to induce hyperfibrinolysis, the latter playing a central role in trauma-induced coagulopathy and mortality [7] [8] [9] [10] .
Antifibrinolytic drugs such as tranexamic acid (trans-4-(aminomethyl)cyclohexanecarboxylic acid) are widely used in haemorrhagic conditions associated with hyperfibrinolysis. Reducing blood loss not only reduces premature death and the need for surgery, but also helps to reduce the need for transfusion, with all the associated risks [11, 12] .
Administration of tranexamic acid to trauma patients has been shown to decrease mortality due to bleeding by 32% if the first bolus was given early (< 1 h), by 21% if given between 1 h and 3 h, whereas administration later than the third hour after trauma seems to increase the risk of death [13] [14] [15] [16] [17] . Since patients may die before reaching hospital [5] , studies have been performed to evaluate the effects of pre-hospital administration of tranexamic acid. A significant effect has been observed on early survival [18, 19] , and the European Trauma Treatment Guidelines now recommend the 'blind' administration of tranexamic acid to trauma patients who are bleeding as early as possible, including before reaching hospital [1, 20] . Most published dosing regimens in trauma consist of an intravenous bolus dose of tranexamic acid 1 g followed by a continuous infusion (1 g over 8 h) [13, 18, 19, 21, 22] . We planned to study plasma levels of tranexamic acid in trauma victims on arrival at hospital, after they had received a single bolus of 1 g in the prehospital setting.
Tranexamic acid pharmacokinetics have previously been described mainly in cardiac surgery [23] [24] [25] [26] [27] , and the doses used in trauma in both large-scale in-hospital and pre-hospital trials were purely empirical, in the absence of pharmacokinetic studies. Hence, data on blood tranexamic acid concentrations and pharmacokinetics in trauma patients are lacking, and may be of great value in improving the dosing regimen and the risk/benefit ratio for administration.
The objectives of this study were to determine the plasma levels of tranexamic acid in victims of trauma when they reached hospital; to build a population model describing the pharmacokinetics of tranexamic acid; and to propose an optimised dosing regimen.
Methods
We gained ethical approval from our local ethics committee (Kantonale Ethikkommission Zurich, Zurich, Switzerland). We conducted this prospective, multicentre study at the University Hospital of Zurich and the Cantonal Hospitals of Lucerne and St. Gallen. We included patients treated by either the emergency medical service (EMS, Schutz und Rettung Zurich, Zurich, Switzerland) or the helicopter emergency medical service (HEMS, Rega, Swiss Air-Ambulance, Garde A erienne, Zurich Airport, Zurich, Switzerland) and referred to one of the level-1 trauma centres mentioned above. We sought delayed informed consent after patients had been stabilised and when they had regained capacity. In the case of a patient's death or continuing disabling medical condition, informed consent was obtained from relatives. We enrolled patients between December 2014 and March 2016.
Inclusion criteria were as follows: all patients with age ≥ 18; severe trauma and/or severe traumatic brain injury; and National Advisory Committee for Aeronautics score ≥ 3. Patients were not studied in cases of pregnancy, inability to give informed consent or to obtain informed consent from relatives, or if no tranexamic acid was given.
Medical treatment was not delayed for study reasons. Patients were treated according to PHTLS (PreHospital Trauma Life Support 8th Edition) for severely traumatised patients. The HEMS (Rega) service performs over 11,000 emergency missions per year; the crew consists of a paramedic, a designated emergency physician and a pilot. The EMS (Schutz und Rettung Zurich) is the largest civil emergency service in Switzerland and operates 35,000 medical emergency missions per year. The team consists of two registered paramedics with an advanced federal diploma of higher education. In the case of life-threatening emergencies such as severely traumatised patients, a designated emergency physician is brought to the scene by a rapid response car. Physicians need to have passed advanced trauma and cardiovascular life support courses.
After obtaining mandatory second venous access line on scene, we collected a citrated blood sample (S-Monovette, Sarstedt, N€ umbrecht, Germany) and a blood gas analysis syringe sample (Radiometer Medical, Bronshoj, Denmark). We then gave a loading dose of tranexamic acid 1 g intravenously on scene, with no further tranexamic acid administration until reaching hospital. On arrival at the hospital emergency department, the same set of blood samples (citrated blood and blood gas sample) was drawn. With respect to fluid resuscitation, patients received balanced lactated crystalloid solution only (Ringerfundin â ; B-Braun Medical, Sempach, Switzerland).
We separated plasma by centrifugation and stored it at À80°C until analysis. Tranexamic acid concentrations were determined in plasma samples using liquid chromatography coupled to mass spectrometry, following a fully validated method [28] . We corrected the measured concentrations to account for the dilution by the citrate anticoagulant in the collection tubes. Haematocrit (Hct) values were determined from the blood gas samples (on-scene and emergency department admission) with an ABL-800 analyser (Radiometer Medical). We recorded the time of trauma, time of tranexamic acid administration and time of blood sampling. Demographic data, type of trauma, injury severity score and anatomical-based abbreviated injury scores were documented or calculated by medical encoders responsible for the annual report for the Trauma Register database of the German Society of Trauma Surgery. We calculated body surface area according to Gehan and George [29] ; 0.0235 9 height(cm) 0.42246 9 weight(kg) 0.51456 . Estimated blood volume was calculated for women (body surface area 9 2.43) and men (body surface area 9 2.53), and we calculated blood loss as estimated blood volume 9 ln(Hct on-scene /Hct Emergency Department ), where ln is the natural logarithm [30, 31] . For pharmacokinetic modelling, a two-compartment open model was applied to the tranexamic acid data:
where A 1 and A 2 are the amounts of drug in the compartments; k 10 = CL/Vc; k 12 = Q/Vc and k 21 = Q/Vp. Values are elimination (CL) and diffusional (Q) clearances, and the volume of central (Vc) and peripheral (Vp) compartments.
We analysed data using the non-linear mixed effect modelling software program Monolix v4.1.4 (Lixoft, Orsay, France) [32] . We estimated parameters by computing the maximum likelihood estimator of the parameters without any approximation of the model (no linearisation), using the stochastic approximation expectation maximisation algorithm combined with a Markov Chain Monte Carlo procedure.
We used a proportional error model to describe the residual variability (e PROP ), and the between-subject variabilities (BSV or g) were ascribed to an exponential error model. We evaluated the effects of demographic and clinical characteristics that may have influenced tranexamic acid pharmacokinetics: body mass index (BMI); weight; age; sex; serum creatinine; blood loss; and volume of fluids administered.
We used the likelihood ratio test, including the log-likelihood, the Akaike information criterion (AIC) and the Bayesian information criterion (BIC) to test different hypotheses regarding the final model, the covariate effect on pharmacokinetic parameters, the residual variability model (proportional vs. proportional plus additive error model), and the structure of the variance-covariance matrix for the between-subject variability parameters. We evaluated the goodness-offit of each model by visual inspection of the observedpredicted (population and individual) concentration scatter plots. We performed 500 simulations from the final model to compute the visual predictive check.
Since there was a single sample per subject, estimating the intra-subject variance was impossible, and we fixed the residual variability to be able to estimate the between-subject variability. We performed a sensitivity analysis to assess the influence of fixing this residual variability, by evaluating the effect of a two-fold change in the value. The values of the estimates were not significantly different (less than 2.5% change for the clearance terms), thereby confirming the acceptability of fixing the residual variability.
We performed statistical analyses with R or GraphPad Prism software (v5.01, San Diego, CA, USA). We checked the assumption of normality with the D'Agostino-Pearson normality test.
Results
We enrolled 73 subjects. The measured concentrations in two of the 73 patients were outliers (> 10r) and were excluded from the analysis. Table 1 . The data were best described by a two-compartment open model. The parameters of the model were the elimination (CL) and diffusional (Q) clearances, and the volume of central (Vc) and peripheral (Vp) compartments. We estimated between-subject variability for CL and Vc using an exponential model and described the residual variability using a proportional error model. The goodness-of-fit of the model was improved when the parameters were allometrically normalised for body-weight, resulting in a significant decrease in between-subject variability. The precision of the estimation did not reach the required standards for Q and for the residual variability. Fixing these parameters to 32.2 and 0.11, respectively, according to previous findings [25] resulted in a decrease in BIC and allowed good estimations for all other parameters. The final covariate model was, thus, significantly better than the covariate-free model and was as follows (normalised for body-weight (BW) to a 70-kg individual):
PWR where i denotes the ith individual. The power (PWR) exponents were set to 0.75 for CL, and Q and 1 for the volume terms.
We found no influence of age, sex, serum creatinine, blood loss and volume of fluids administered on pharmacokinetics. Table 2 shows the final population pharmacokinetic estimates, and Supporting Information Figure S1 shows representative pharmacokinetic time courses for 12 patients. In the prediction-corrected visual predictive check plot (Figure 1) , the percentiles of observed concentrations are well in the middle of the corresponding simulated 95%CI bands, demonstrating that the chance of any model mis-specification regarding the fixed or random effect is very unlikely. Diagnostic plots showing the normalised prediction distribution errors (NPDE) residues vs. time and predicted concentrations are proposed as Supporting Information Figure S2 . The NPDE metrics is a very conservative residual test, so the well-distributed NPDE around the zero ordinate further suggests that the final model was appropriate. The NPDE statistics showed that their distribution was not different to a normal distribution (p = 0.593); that the mean was not different from 0 (p = 0.897); and that the variance was not different from 1 (p = 0.996). The pharmacokinetic model was used to propose an optimised dosing regimen aimed at maintaining blood concentrations above 20 lg.ml À1 or above 150 lg.ml
À1
, respectively, as long as required. The 20 lg.ml À1 threshold has been shown to inhibit fibrinolysis in vitro [33, 34] , whereas concentrations in the range 120-150 lg.ml À1 were previously recommended in cardiac surgery studies, where patients with concentrations in this range had better clinical outcomes than patients with lower concentrations [23, 25, 35] . To maintain the lowest target concentration (20 lg.ml À1 ), a 'one size fits all' (non-weight-adjusted) dosing regimen and a bodyweight-adjusted dosing regimen were developed. The 'one size fits all' approach would consist of the administration of a loading dose of tranexamic acid 1 g pre-hospital, which would be sufficient to maintain a concentration > 20 lg.ml À1 for at least 1.5 h. Then, a continuous infusion of tranexamic acid 0.25 g.h À1 could be given to maintain the target concentration. For the bodyweight-adjusted approach, a dosing starting with a bolus of tranexamic acid 6.9 mg.kg À1 given over one min, immediately followed by an infusion of tranexamic acid 2.6-3.3 mg.kg
.h À1 , would allow a concentration > 20 lg.ml À1 to be ) for as long as needed ( Figure 2 , Table 3 ). The dosing proposal and individual pharmacokinetic parameter estimates for patients with bodyweights of between 50 kg and 120 kg receiving these dosing schemes are presented in Table 3 .
Discussion
This is, to our knowledge, the first study to examine the plasma levels and pharmacokinetics of tranexamic acid in patients with severe trauma who had received pre-hospital tranexamic acid. The pharmacokinetics of tranexamic acid have previously been described mainly during cardiac surgery, and the data also fitted a twocompartment model [23] [24] [25] [26] [27] . The allometric adjustment of volumes and clearances explained a significant part of the between-subject variability. This allometric scaling used power exponents of 0.75 and 1 for clearance , bodyweight-adjusted scheme: 6.9 mg.kg À1 in 1 min followed by a 2.6-3.3 mg. kg .h À1 infusion for patients with bodyweights between 50 kg and 120 kg. In (b) and (c), the red line represents the median concentration and the light blue areas represent the 95% CI. The grey dotted horizontal lines represent the threshold target concentrations. TXA, tranexamic acid. and volume terms, respectively, as previously described in the allometric theory [36, 37] .
The parameter estimates are in the range of the values described in previous population models, with a clearance in the range 2.45-7.4 l.h À1 and an apparent volume of distribution between 16.5 l and 46.3 l for a 70 kg individual [23] [24] [25] 27] . For its antifibrinolytic activity, tranexamic acid inhibits the degradation of fibrin molecules by binding to lysine-binding sites on plasmin and plasminogen [38] . Each plasminogen molecule has up to five binding sites for tranexamic acid, with one site of high affinity (Kd = 0.17 lg.ml
À1
) and others with lower affinity (Kd = 117-157 lg.ml À1 ) [38, 39] . In keeping with this, a concentration of 10 lg.ml À1 inhibited fibrinolysis by 80% in the first pharmacologic studies in pig tissues, but concentrations of 100 lg.ml À1 (i.e. a 10-fold increase) were required to reach 98% inhibition [33] . Moreover, the nature of the plasminogen activator may impact on the efficacy of tranexamic acid; in vitro, a concentration of 31 lg.ml À1 of tranexamic acid was required to fully inhibit tPA-induced fibrinolysis, whereas a concentration up to about 157 lg.ml À1 was required when uPA was used as an activator [38] . In a mouse model of traumatic brain injury, tPA played the predominant role in brain damage in the absence of delayed intracerebral haemorrhage, but uPA was the major contributor to delayed intracerebral bleeding [6] . In this model, the inhibition of the tPA-activated fibrinolysis by tranexamic acid was maximal and reached a plateau at a concentration of 15.7 lg.ml À1 , whereas when plasminogen was activated by uPA, a plateau effect was still not reached at a concentration of 78.5 lg.ml
, suggesting that the efficacy of drug may be improved with higher concentrations.
Furthermore, in addition to their role in fibrinolysis, plasminogen and plasmin also play a role in inflammation, chemo-attraction and tissue remodelling [40] . In vitro, tranexamic acid was able to suppress plasmininduced platelet activation at a concentration of 16 lg.ml À1 and to inhibit the plasmin-induced production of pro-inflammatory cytokines by human monocytes at concentrations of 47.1 lg.ml À1 and 471 lg.ml À1 [41, 42] . At concentrations as high as 126-252 lg.ml
, tranexamic acid may have increased the formation of thrombin [43] . To summarise the pharmacokinetic/pharmacodynamic relationship, lower tranexamic acid concentrations (%20 lg.ml À1 ) may be enough to inhibit most of the tPA-induced fibrinolysis. However, much higher concentrations (%150 lg.ml À1 ) may be required to inhibit uPA-induced fibrinolysis or to exert an effect on other parameters. These differences may also translate into differences in clinical efficacy, despite a lack of robust evidence. This hypothesis is supported by reports in cardiac surgery showing lower transfusion requirements and lower rates of return to theatre with dosing schemes providing the highest blood concentrations (%150 lg.ml À1 ), when compared with lower dosing schemes providing concentrations enough to only inhibit the tPA-mediated fibrinolysis Dosing regimen to rapidly obtain the desired plateau concentration as a function of bodyweight. The first bolus (given in approximately 1 min) is followed by a continuous infusion to maintain the target concentration as long as needed.
(30-60 lg.ml À1 ) [25, 35] , thereby justifying the recommendation that concentrations in the range 126-150 lg.ml À1 are required in this setting [23, 25] . However, avoiding levels that are too high is important for preventing harmful side-effects such as seizures, which may occur a high blood concentrations [44] . With respect to trauma, this study shows that the dosing schemes used in most trials may provide concentrations that fall below 20 lg.ml À1 6 h after the initial loading dose, as observed in more than 21% of the patients in this study. Two-thirds of patients that die from exsanguination die within the first 6 h after injury, and 80% of blood products, are transfused in the same time-frame [45, 46] . This may suggest that the optimal tranexamic acid concentration was not reached. Therefore, we sought to optimise the drugdosing regimen.
For the reasons discussed previously, we propose two regimens allowing the maintenance of concentrations above either 20 lg.ml À1 or 150 lg.ml À1 . For the lowest target concentration, we propose either a 'one size fits all' regimen (single bolus followed with a continuous infusion after 1.5 h), or a bodyweight-adjusted regimen with a bolus dose immediately followed by a continuous infusion. For the highest target concentration, only bodyweight-adjusted schemes are feasible to avoid reaching blood concentrations in the toxic range. First, our findings confirm that re-dosing as soon as possible after a first bolus dose has been given is mandatory to maintain the desired blood concentration. Then, appropriate dosing according to tranexamic acid pharmacokinetics is suggested. Finally, we propose that bodyweight-adjusted doses should be used, which should improve the pharmacokinetic profiles in patients and allow concentrations to be maintained in a narrow range in patients of all bodyweights. If the objective is to maintain an effective concentration over 8 h, the total doses with the bodyweight-adjusted scheme would be between 27.9 mg.kg À1 and 33.1 mg.kg À1 for patients weighting between 50 kg and 120 kg, for a target concentration of 20 lg.ml
. This means that the total dose will be lower or equivalent to the doses actually used in clinical trials (tranexamic acid 1 g over 10 min then 1 g over 8 h, corresponding to doses between 20 mg.kg À1 and 40 mg.kg À1 for the same bodyweight range), but the distribution over time is different. By contrast with these schemes, our recommended regimen allows maintenance of the target concentration over 8 h and reduces the peak concentration by about two-to fourfold. If the target concentration was 150 lg.ml
, the total dose given over 8 h would be 200-240 mg.kg À1 , which is lower than doses used by some teams in paediatric cardiac surgery (up to 300 mg.kg À1 in a shorter time period) [47, 48] . The total tranexamic acid doses used in trauma studies up to now were below about 40 mg.kg
. Obviously, using higher doses to maintain a blood concentration around 150 lg.ml À1 will require close monitoring of adverse events and studies addressing drug safety will be required. Importantly, concentrations as high as 150 lg.ml À1 have already been reached in trials without a significant impact on drug safety [25, 35] , whereas in other trials, concentrations ≥ 700 lg.ml À1 were predicted [24] .
With the doses used in previous in-hospital studies in trauma patients, a mean decrease of mortality of 10% was observed [14] . With respect to the pharmacological data presented above and to the kinetics of production of tPA and uPA [6] , it is likely that a greater decrease in mortality might be expected by using an optimised dosing regimen aimed at targeting a most effective concentration and by giving the first dose pre-hospital as early as possible. This study was not powered to assess clinical outcomes (survival, number of transfusions needed, thrombotic or neurologic events).
Our study has some limitations. We analysed a single blood sample per patient. This impaired the estimation of residual variability, which was fixed according to a previous study, as was the diffusional clearance [25] . However, the analysis of sparse data with population pharmacokinetic analysis remains possible and reliable [49] , and the sampling times in this study were between 0.3 h and 2.5 h, a time range that is not so small relative to the very short drug half-life of approximately 1 h (see also Supporting Information, Table S1 ). The shape of the pharmacokinetic curve was well described in this time interval, and allowed us to build a model and estimate the parameters with an accuracy lower than 40% and to obtain conclusive goodness-of-fit plots. The sensitivity test performed on the residual variability was also successful. Furthermore, we performed a new analysis of the results using a Bayesian approach to confirm the validity of the proposed population model. The individual estimates were well estimated and close to the estimates from the population pharmacokinetic analysis (see also Supporting Information, Data S1). All patients had normal kidney function when enrolled in the study, and thus, our results cannot be extrapolated to other patient populations, especially those with renal impairment. In addition, our optimised dosing regimen must be validated in a future prospective trial. Finally, surgery and trauma may not be fully comparable, and there may be differences in the optimal target concentration for each situation, according to the specific kinetics of tPA and uPA release and to differences in the potency of tranexamic acid towards each activator.
Our study is the first to report tranexamic acid plasma levels and pharmacokinetics in trauma patients. The knowledge of tranexamic acid pharmacokinetics is essential to determine the best dosage regimen, and the developed model was used to propose an optimised regimen. However, due to the lack of knowledge of pharmacodynamics and safety profile in trauma patients, further clinical studies are required to determine the adequate therapeutic window of tranexamic acid for this indication. Our proposed dosing regimens may be used to conduct such studies in order to maintain controlled blood concentrations.
Supporting Information
Additional Supporting Information may be found in the online version of this article:
Data S1. Optimisation of the dosage of tranexamic acid in trauma patients with population pharmacokinetic analysis. Table S1 . Pharmacokinetic parameters for tranexamic acid in trauma patients between 50 and 120 kg. Table S2 . Parameter estimates using a Bayesian approach. Table S3 . Individual parameter estimates using a Bayesian approach. Figure S1 . Individual pharmacokinetic time courses of tranexamic acid in 12 representative patients: (+, observations; red line, mean population prediction; green line, individual predictions). Figure S2 . Normalised prediction distribution errors (NPDE) residues vs. time (left) and predicted concentrations (right). Figure S3 . Individual pharmacokinetic time courses of tranexamic acid with the Bayesian analysis (+, observations; green line, individual predictions).
